Thrombopoietin receptor agonists in hereditary thrombocytopenias.

Abstract excerpt

Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought. Most HTPs do not have effective treatments, except for platelet transfusion when bleeding occurs and in preparation...

Topics

Join the communities discussing this publication.

• Benzoates
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Hydrazines
• Purpura, Thrombocytopenic, Idiopathic